Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Imel Biotherapeutics Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are split between 2 distinct examiners and 2 distinct art units. HAMA, JOANNE is identified as the busiest examiner with 1 pending office action. This 1:1 ratio between pending actions and examiners suggests a diversified prosecution across different technical sub-specialties or art units.
The 2 pending office actions are distributed across 2 distinct art units, indicating that the company is pursuing multiple technical paths within the Biotechnology & Pharmaceuticals sector. With 2 distinct examiners involved, the company must manage two separate prosecution timelines. HAMA, JOANNE handles 1 pending office action, which is the same volume as the other examiner. This lack of concentration across 2 distinct examiners and 2 distinct art units means that the outcome of each of the 2 pending office actions is independent of the other.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562815 | METHODS AND COMPOSITIONS FOR GENERATING MITOCHONDRIA REPLACED LYMPHOID CELLS | KIM, TAEYOON | — |
| 18562816 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE CELL EXHAUSTION USING MITOCHONDRIA REPLACEMENT | HAMA, JOANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562815 | METHODS AND COMPOSITIONS FOR GENERATING MITOCHONDRIA REPLACED LYMPHOID CELLS | KIM, TAEYOON | — |
| 18562816 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE CELL EXHAUSTION USING MITOCHONDRIA REPLACEMENT | HAMA, JOANNE | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562815 | METHODS AND COMPOSITIONS FOR GENERATING MITOCHONDRIA REPLACED LYMPHOID CELLS | KIM, TAEYOON | 1631 | §103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18562816 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE CELL EXHAUSTION USING MITOCHONDRIA REPLACEMENT | HAMA, JOANNE | 1647 | §103DP | Non-Final OA | — | Pending | Nov 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImel Biotherapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Taeyoon Kim has the most, with 1 of Imel Biotherapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
